TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01256008

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical Management
Description: Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible.
Study: NCT02114216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic mucosal biopsy
Description: endoscopic mucosal biopsy was undertaken for every participant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic mucosal biopsy
Description: endoscopic mucosal biopsy was undertaken for every participant.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: endoscopic mucosal biopsy
Description: endoscopic mucosal biopsy was undertaken for every participant.
Study: NCT01350583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3)
Description: Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
Study: NCT03056885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional One-Lung Ventilation
Description: Vt 10 ml/kg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protective One-lung ventilation
Description: Vt 5 ml/kg
Study: NCT03333447

Intervention type: OTHER
Intervention: MRI
Study: NCT01795209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit
Study: NCT02261064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine high dose
Study: NCT01795209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue laser
Description: In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3
Study: NCT02261064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Japanese meal
Study: NCT01667497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fampridine SR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02977364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Study: NCT01795209

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Rescue laser
Description: In the Lucentis group: performed if BCVA \< 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA \< 20/40 or CFT ≥ 350um from Month 3
Study: NCT03169712

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for PTSD
Description: Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for PTSD
Description: Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy
Description: IRT protocol published by Nappi and collaborators (2010)
Study: NCT03466437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass-fiber post and composite resin restoration
Description: Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass-fiber post and metalceramic crown
Description: Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
Study: NCT02977364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241
Study: NCT01926951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surround Sound Externally Focused Therapeutic Ultrasound
Description: Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
Study: NCT02281227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin compression
Description: skin compression with an indicator for determination of needle entry point

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin compression
Description: skin compression with an indicator for determination of needle entry point
Study: NCT04153981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT00783835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Methylphenidate
Description: Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
Study: NCT03256669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical incision
Description: exploration through umbilical incision
Study: NCT03764319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-protective ventilator settings
Description: 4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 \< Plateau pressure \< 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume \> 4 mL/kg Predicted body weight (PBW)); \< 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ventilator settings
Description: 12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
Study: NCT02168634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Description: 5U botulinum toxin in 1c.c. normal saline, local injection
Study: NCT03244384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02168634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1cc normal saline, local injection
Study: NCT00772291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: pregabalin 150-600mg/day during 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo drug during 8 weeks
Study: NCT03244384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02937272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally
Study: NCT04444102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga-based stretching
Description: Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga-based stretching
Description: Different yoga postures (ASANA) were isolated from conventional yoga practice to stretch different muscle groups.~Muscle groups stretched: hip extensor and adductors, hip \& plantar flexors, shoulder extensors, shoulder horizontal adductors, shoulder extensors-adductor, wrist flexor, trunk extensors, lateral flexors, and trunk rotators.
Study: NCT02900339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
Study: NCT00807378

Intervention type: OTHER
Intervention: LUMBAR PUNCTURE
Description: LUMBAR PUNCTURE FFOR CSF COLLECTION

Intervention type: OTHER
Intervention: LUMBAR PUNCTURE
Description: LUMBAR PUNCTURE FFOR CSF COLLECTION
Study: NCT00425295

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Simulation Training
Description: Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
Study: NCT00971230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02266004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Anodal tDCS will be applied for the duration of the walking training at 2 milliamps with IOMED Phoresor.
Study: NCT03466437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cast-metal post and metalceramic crown
Description: Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
Study: NCT00425295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Simulation Training
Description: Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
Study: NCT03146013

Intervention type: DIAGNOSTIC_TEST
Intervention: MP Diagnostics HTLV Blot 2.4
Description: HTLV I/II Confirmation and Differentiation
Study: NCT02266004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: locomotor training
Description: An individualized dual-task walking program for approximately 30 minutes.
Study: NCT00827632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Study: NCT04664712

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tendisulfur Pro
Description: Dietary supplement based on Methylsulfonylmethane (2.5 g), hydrolyzed collagen (1 g), L-arginine (1 g), L-lysine (500 mg), Vitamin C (500 mg), Bromelain (200 mg), Chondroitin sulfate (150 mg), Glucosamine (150 mg) \[17, 18\], dry extracts of turmeric (100 mg), Boswellia (100 mg) and Myrrh (50 mg)
Study: NCT01666860

Intervention type: PROCEDURE
Intervention: Anterior Lumbar Interbody Fusion procedure
Study: NCT03251872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets
Study: NCT01085604

Intervention type: OTHER
Intervention: Core Stabilization
Description: The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis\[TrA\], lumbar multifidus\[LM\]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning.
Study: NCT00126672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Study: NCT02032186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium citrate
Description: Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium citrate
Description: Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
Study: NCT04432467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous adipose tissue-derived mesenchymal stem cells
Study: NCT02937272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally
Study: NCT04432467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study: NCT00264095

Intervention type: PROCEDURE
Intervention: Oncological surgery
Description: surgery is primary observed intervention and blood loss is between 500-3000 ml
Study: NCT00408291

Intervention type: PROCEDURE
Intervention: Winsta PH osteosynthesis device
Description: The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
Study: NCT01980225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collapse
Description: inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
Study: NCT06031376

Intervention type: DRUG
Intervention: Fruquintinib
Description: 5mg once daily for 14 days on/7 days off, over a 21-day cycle

Intervention type: DRUG
Intervention: PD-1 inhibitors
Description: The anti-PD-1 antibody was administered intravenously on day 1, and its recommended dosage was as follows: nivolumab: 240 mg, every 2 weeks; pembrolizumab, camrelizumab, and sintilimab: 200 mg every 3 weeks; and toripalimab: 240 mg every 3 weeks.

Intervention type: DRUG
Intervention: Trifluridine/Tipiracil
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab 5 mg /kg, intravenously on days 1,15,every 28 days
Study: NCT00927329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dust mite inhalation
Description: Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
Study: NCT02069249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sleep intervention
Description: Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
Study: NCT02937272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Study: NCT02069249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Nutrition intervention
Description: Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
Study: NCT04176536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: Capsules
Study: NCT03215667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft CLASSIC (beta-Tricalcium Phosphate)
Description: easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
Study: NCT02655406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Class 2 compression stockings
Study: NCT01569997

Intervention type: OTHER
Group type: OTHER
Intervention: MultiDisciplinary Team Meetings (MDTM)
Description: The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
Study: NCT04289194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCR040 (Phase 1)
Description: (Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Phase 2)
Description: (Phase 2) Intravenous administration of vehicle solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCR040 (Phase 2)
Description: (Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)
Study: NCT00374036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC
Description: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan
Study: NCT02475629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibalizumab
Description: 2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
Study: NCT03907813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: liposomal bupivacaine wound infiltration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infiltration
Description: saline wound infiltration
Study: NCT02225236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom Intervention
Study: NCT03676205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Platelet-Rich Plasma

Intervention type: OTHER
Group type: OTHER
Intervention: Traumeel
Description: Homeophatic Treatment